Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction-A Review of Literature

Title: Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction-A Review of Literature

Authors: Sruthi Srinivasan, T.A.Naufal Rizwan

DOI: http://dx.doi.org/10.18535/jmscr/v4i8.18

Abstract

References

Corresponding Author

Abstract

The objective of this review is to do a literature search on the effectiveness of isosorbide mononitrate in heart failure patients with preserved ejection fraction. Heart failure with preserved ejection fraction (HF-PEF) also known as diastolic heart failure is the clinical syndrome of heart failure associated with near-normal systolic function. It is a manifestation of signs and symptoms of heart failure with an ejection fraction greater than 45% and is characterised by reduced ventricular filling and elevated left ventricular filling pressure. There is an increased risk for the occurrence of congested cardiac failure or atrial fibrillation in such patients. Many drugs like diuretics, beta blockers, ACE inhibitors can be used to treat the above condition although nitrates being the most common choice of drugs to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. This review aims at studying the effect of isosorbide mononitrate in heart failure patients with a preserved ejection fraction. Heart failure is a serious problem and can be fatal. Hence it is ideal to know the correct choice of medical treatment of such conditions.

References

1. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysio-logy, diagnosis, and treatment. Eur Heart J. 2011; 32:670–679. [PubMed: 21138935]

2. Phan TT, Shivu GN, Abozguia K, et al. The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics. Int J Cardiol. 2012; 158:337–343. [PubMed: 21794933]

3. Liu Y, Haddad T, Dwivedi G. Heart failure with preserved ejection fraction: current understanding and emerging concepts. CurrOpinCardiol. 2013; 28:187–196. [PubMed: 23274284]

4. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth. J Am Coll Cardiol 2010; 55: 526 –537.

5. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2009; 53: 905–918.

6. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550.

7. Doughty RN, Whalley GA, Walsh HA, et al. CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004; 109: 201–206.

8. Elkayam U, Johnson JV, Shotan A, Bokhari S, Solodky A, Canetti M, Wani OR, Karaalp IS. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation. 1999; 99:2652–2657. [PubMed: 10338458]

9. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010; 3:588–595. [PubMed: 20543134]

10. Penicka M, Bartunek J, Trakalova H, Hrabakova H, Maruskova M, Karasek J, Kocka V. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: A pressurevolume loop analysis. J Am Coll Cardiol. 2010; 55:1701–1710. [PubMed: 20394874]

11. Battock DJ, Levitt PW, Steele PP. Effects of isosorbidedinitrate and nitroglycerin on central circulatory dynamics in coronary artery disease. Am Heart J. 1976; 92:455–458. [PubMed: 822703]

12. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol. 1996; 77:41C–51C. [PubMed: 8540455]

13. Packer M, Medina N, Yushak M, Lee WH. Comparative effects of captopril and isosorbidedinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: Results of a randomized crossover study. Am Heart J. 1985; 109:12931299. [PubMed: 3890506]

14. Haber HL, Simek CL, Bergin JD, Sadun A, Gimple LW, Powers ER, Feldman MD. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance. J Am Coll Cardiol. 1993; 22:251–257. [PubMed: 8509548]

15. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014; 63:2817–2827. [PubMed: 24768876]

16. Yaginuma T, Avolio A, O’Rourke M, Nichols W, Morgan JJ, Roy P, Baron D, Branson J, Feneley M. Effect of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. Cardiovasc Res. 1986; 20:153–160. [PubMed: 3085950]

17. Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and aii inhibition on pulse wave reflection in hypertension. Hypertension. 2003; 41:297–301. [PubMed: 12574098]

18. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011; 123:2006–2013.; discussion 2014. [PubMed: 21555723]

19. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of s-nitrosothiols as active intermediates. The Journal of pharmacology and experimental therapeutics. 1981; 218:739–749. [PubMed: 6115052]

20. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010; 56:845–854. [PubMed: 20813282]

21. Schwarz M, Katz SD, Demopoulos L, Hirsch H, Yuen JL, Jondeau G, LeJemtel TH. Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure. Circulation. 1994; 89:1609–1614. [PubMed: 8149528]

22. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013; 62:263–271. [PubMed: 23684677]

23. Munzel T, Daiber A, Gori T. Nitrate therapy: New aspects concerning molecular action and tolerance. Circulation. 2011; 123:2132–2144. [PubMed: 21576678]

24. Gupta D, Georgiopoulou VV, Kalogero-poulos AP, Marti CN, Yancy CW, Gheorghiade M, Fonarow GC, Konstam MA, Butler J. Nitrate therapy for heart failure: Benefits and strategies to overcome tolerance. JACC Heart failure. 2013; 1:183–191. [PubMed: 24621868]

25. Munzel T, Daiber A, Gori T. Nitrate therapy: New aspects concerning molecular action and tolerance. Circulation. 2011; 123:2132–2144. [PubMed: 21576678]

26. Elkayam U, Roth A, Mehra A, Ostrzega E, Shotan A, Kulick D, Jamison M, Johnston JV, Rahimtoola SH. Randomized study to evaluate the relation between oral isosorbidedinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation. 1991; 84:2040–2048. [PubMed: 1934379]

27. Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R, Watts LE, Garutti RJ, Ferraresi R, Casareto R. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993; 72:1249–1256. [PubMed: 8256699]

28. Gunasekara NS, Noble S. Isosorbide 5-mononitrate: A review of a sustained-release formulation (imdur) in stable angina pectoris. Drugs. 1999; 57:261–277. [PubMed: 10188765]

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 10 November 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search